| 摘要 |
The invention features doxorubicin or Doxil in combination with a checkpoint inhibitor (e.g., an anti-CTLA-4 antibody, anti-PD-1 antibody, an anti-PD-L1 antibody, GITR ligand, or OX40 fusion protein (FP) and methods of using the combination to enhance anti-tumor activity in a subject. |
